SAN DIEGO—(BUSINESS WIRE)—Nov. 27, 2018—ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical companyfocused on the development and commercialization of innovative medicinesto address unmet medical needs in central nervous system (CNS)disorders, today announced the pricing of an underwritten publicoffering of 16,176,471 shares of its common stock, offered at a price tothe public of $17.00 per share. The gross proceeds from this offering toACADIA are expected to be approximately $275.0 million, before deductingunderwriting discounts and commissions and other estimated offeringexpenses payable by ACADIA. ACADIA has granted the underwriters a 30-dayoption to purchase up to an aggregate of 2,426,470 additional shares ofcommon stock. The offering is expected to close on November 30, 2018,subject to customary closing conditions.
BofA Merrill Lynch, J.P. Morgan Securities LLC and Goldman Sachs & Co.LLC are acting as the joint book-running managers for the offering.Cowen and Company, LLC is acting as lead manager and Cantor Fitzgerald &Co., JMP Securities LLC and Needham & Company, LLC are acting asco-managers for the offering.
The shares of common stock described above are being offered by ACADIApursuant to a shelf registration statement filed by ACADIA with theSecurities and Exchange Commission (SEC) that became automaticallyeffective upon filing. A preliminary prospectus supplement related tothe offering was filed with the SEC and is available on the SEC’swebsite located at http://www.sec.gov.Copies of the final prospectus supplement and the accompanyingprospectus related to this offering, when available, may be obtainedfrom BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rdFloor, Charlotte, NC 28255-0001, Attn: Prospectus Department, Email: dg.prospectus_requests@baml.com,or from J.P. Morgan Securities LLC, Attention: Broadridge FinancialSolutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at(866) 803-9204, or by email to: prospectus-eq_fi@jpmchase.com,or from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200West Street, New York, NY 10282, or by telephone at (866) 471-2526, orby email to: prospectus-ny@nyemail.gs.com.
This press release shall not constitute an offer to sell or thesolicitation of an offer to buy these securities, nor shall there be anysale of these securities in any state or other jurisdiction in whichsuch offer, solicitation or sale would be unlawful prior to theregistration or qualification under the securities laws of any suchstate or other jurisdiction.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceuticalcompany focused on the development and commercialization of innovativemedicines to address unmet medical needs in central nervous systemdisorders. ACADIA has developed and is commercializing the first andonly medicine approved for the treatment of hallucinations and delusionsassociated with Parkinson’s disease psychosis. In addition, ACADIA hasongoing clinical development efforts in additional areas withsignificant unmet need, including dementia-related psychosis,schizophrenia inadequate response, schizophrenia-negative symptoms,major depressive disorder, and Rett syndrome.
Forward-Looking Statements
Statements in this press releasethat are not strictly historical in nature are forward-lookingstatements. These statements include but are not limited to statementsrelated to the expected proceeds and timing of the offering of commonstock by ACADIA. These statements are only predictions based on currentinformation and expectations and involve a number of risks anduncertainties. Actual events or results may differ materially from thoseprojected in any of such statements due to various factors, includingmarket risks and uncertainties and the satisfaction of customary closingconditions for an offering of securities. For a discussion of these andother factors, please refer to ACADIA’s annual report on Form 10-K forthe year ended December 31, 2017 as well as ACADIA’s subsequent filingswith the Securities and Exchange Commission. You are cautioned not toplace undue reliance on these forward-looking statements, which speakonly as of the date hereof. This caution is made under the safe harborprovisions of the Private Securities Litigation Reform Act of 1995. Allforward-looking statements are qualified in their entirety by thiscautionary statement and ACADIA undertakes no obligation to revise orupdate this press release to reflect events or circumstances after thedate hereof, except as required by law.
Source: ACADIA Pharmaceuticals Inc.
Investor Contact:
ACADIA Pharmaceuticals Inc.
ElenaRidloff, CFA
(858) 558-2871
ir@acadia-pharm.com
Media Contact:
ACADIA Pharmaceuticals Inc.
MaurissaMessier
(858) 768-6068
media@acadia-pharm.com